Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Evaluating the Safety and Imaging Characteristics of 18F-LY3546117 Injection in Subjects Who Are Undergoing Treatment With Immune Checkpoint Inhibitors

NCT04721756 is registered in ClinicalTrials.gov with Avid Radiopharmaceuticals as lead sponsor.

NCT NCT04721756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04721756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Evaluating the Safety and Imaging Characteristics of 18F-LY3546117 Injection in Subjects Who Are Undergoing Treatment With Immune Checkpoint Inhibitors
Lead sponsor
Avid Radiopharmaceuticals
Phase
Phase 1
Overall status
Unknown status
Start date
April 12, 2022
Completion date
April 30, 2024
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, neoplasms malignant